Sarepta Soars On New Hope For Muscular-Dystrophy Drug
Sarepta Therapeutics (SRPT) stock jumped more than 50% in early trading Wednesday, to an eight-month high, after the company said late Tuesday that the FDA had finally agreed to a refiling plan for its Duchenne muscular dystrophy (DMD) drug eteplirsen. Sarepta said the FDA agreed to a rolling submission plan, with the first batch of data delivered this week and the rest by midyear. That’s in line with previous company guidance, but investors had